Ma Q - Search Results

1

Race/Ethnicity and Protease Inhibitor Use Influence Plasma Tenofovir Exposure in Adults Living with HIV-1 in AIDS Clinical Trials Group Study A5202.

Bednasz CJ, Venuto CS, Ma Q, Daar ES, Sax PE, Fischl MA, Collier AC, Smith KY, Tierney C, Acosta EP, Mager DE, Morse GD; AIDS Clinical Trials Group Study A5202 Team. Bednasz CJ, et al. Among authors: ma q. Antimicrob Agents Chemother. 2019 Mar 27;63(4):e01638-18. doi: 10.1128/AAC.01638-18. Print 2019 Apr. Antimicrob Agents Chemother. 2019. PMID: 30642925 Free PMC article. Clinical Trial.

2

Update on the pharmacokinetic aspects of antiretroviral agents: implications in therapeutic drug monitoring.

Slish JC, Catanzaro LM, Ma Q, Okusanya OO, Demeter L, Albrecht M, Morse GD. Slish JC, et al. Among authors: ma q. Curr Pharm Des. 2006;12(9):1129-45. doi: 10.2174/138161206776055787. Curr Pharm Des. 2006. PMID: 16515491 Review.

3

Pharmacokinetic drug interactions with non-nucleoside reverse transcriptase inhibitors.

Ma Q, Okusanya OO, Smith PF, Dicenzo R, Slish JC, Catanzaro LM, Forrest A, Morse GD. Ma Q, et al. Expert Opin Drug Metab Toxicol. 2005 Oct;1(3):473-85. doi: 10.1517/17425255.1.3.473. Expert Opin Drug Metab Toxicol. 2005. PMID: 16863456 Review.

4

Multidrug resistance 1 polymorphisms and trough concentrations of atazanavir and lopinavir in patients with HIV.

Ma Q, Brazeau D, Zingman BS, Reichman RC, Fischl MA, Gripshover BM, Venuto CS, Slish JC, DiFrancesco R, Forrest A, Morse GD. Ma Q, et al. Pharmacogenomics. 2007 Mar;8(3):227-35. doi: 10.2217/14622416.8.3.227. Pharmacogenomics. 2007. PMID: 17324111

5

Drug interactions between proton pump inhibitors and antiretroviral drugs.

McCabe SM, Smith PF, Ma Q, Morse GD. McCabe SM, et al. Among authors: ma q. Expert Opin Drug Metab Toxicol. 2007 Apr;3(2):197-207. doi: 10.1517/17425255.3.2.197. Expert Opin Drug Metab Toxicol. 2007. PMID: 17428151 Review.

6

HIV pharmacotherapy issues, challenges, and priorities in sub-Saharan African countries.

Maponga CC, Ma Q, Slish JC, Morse GD. Maponga CC, et al. Among authors: ma q. Top HIV Med. 2007 Jun-Jul;15(3):104-10. Top HIV Med. 2007. PMID: 17598930 Free article. Review.

7

Interaction between buprenorphine and atazanavir or atazanavir/ritonavir.

McCance-Katz EF, Moody DE, Morse GD, Ma Q, DiFrancesco R, Friedland G, Pade P, Rainey PM. McCance-Katz EF, et al. Among authors: ma q. Drug Alcohol Depend. 2007 Dec 1;91(2-3):269-78. doi: 10.1016/j.drugalcdep.2007.06.007. Epub 2007 Jul 23. Drug Alcohol Depend. 2007. PMID: 17643869 Free PMC article.

8

Assessing the impact of substance use and hepatitis coinfection on atazanavir and lopinavir trough concentrations in HIV-infected patients during therapeutic drug monitoring.

Slish J, Ma Q, Zingman BS, Reichman RC, Fischl MA, Gripshover B, Forrest A, Brazeau D, Boston NS, Catanzaro L, DiFrancesco R, Morse GD. Slish J, et al. Among authors: ma q. Ther Drug Monit. 2007 Oct;29(5):560-5. doi: 10.1097/FTD.0b013e31806db8ae. Ther Drug Monit. 2007. PMID: 17898644

9

Advances in pharmacogenomics of antiretrovirals: an update.

Ma Q, Brazeau D, Forrest A, Morse GD. Ma Q, et al. Pharmacogenomics. 2007 Sep;8(9):1169-78. doi: 10.2217/14622416.8.9.1169. Pharmacogenomics. 2007. PMID: 17924832 Review.

10

Pharmacokinetic interaction between efavirenz and dual protease inhibitors in healthy volunteers.

Ma Q, Forrest A, Rosenkranz SL, Para MF, Yarasheski KE, Reichman RC, Morse GD; ACTG A5043 Protocol Team, DAIDS, NIH. Ma Q, et al. Biopharm Drug Dispos. 2008 Mar;29(2):91-101. doi: 10.1002/bdd.597. Biopharm Drug Dispos. 2008. PMID: 18041735 Free PMC article. Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

9,633 results

Search Page